ArticleStem cells international2018
Human Neonatal Thymus Mesenchymal Stem Cells Promote Neovascularization and Cardiac Regeneration.
Article in Stem cells international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Time trends in mortality of congenital heart disease in children aged 0-14 years: a global, regional, and national cohort analysis from 1990 to 2021 using the global burden of disease study.Frontiers in public health · 2025Article
- A review of the evidence to support electrical stimulationRegenerative therapy · 2023Review
- Mesodermal Derivatives of Pluripotent Stem Cells Route to Scarless Healing.International journal of molecular sciences · 2023Review
- Hybrid techniques for myocardial regeneration: state of the art and future perspectives.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022Review
- Key Factors for Thymic Function and Development.Frontiers in immunology · 2022Review
- 3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice.Cell death & disease · 2021Article
- Tissue-specific angiogenic and invasive properties of human neonatal thymus and bone MSCs: Role of SLIT3-ROBO1.Stem cells translational medicine · 2020Article
- The use of large animals to facilitate the process of MSC going from laboratory to patient-'bench to bedside'.Cell biology and toxicology · 2020Review
- The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases.Frontiers in pediatrics · 2020Review
- Enhanced Effect of IL-1Stem cells international · 2020Article
- Human Neonatal Thymus Mesenchymal Stem/Stromal Cells and Chronic Right Ventricle Pressure Overload.Bioengineering (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newborns with critical congenital heart disease are at significant risk of developing heart failure later in life. Because treatment options for end-stage heart disease in children are limited, regenerative therapies for these patients would be of significant benefit. During neonatal cardiac surgery, a portion of the thymus is removed and discarded. This discarded thymus tissue is a good source of MSCs that we have previously shown to be proangiogenic and to promote cardiac function in an in vitro model of heart tissue. The purpose of this study was to further evaluate the cardiac regenerative and protective properties of neonatal thymus (nt) MSCs. We found that ntMSCs expressed and secreted the proangiogenic and cardiac regenerative morphogen sonic hedgehog (Shh) in vitro more than patient-matched bone-derived MSCs. We also found that organoid culture of ntMSCs stimulated Shh expression. We then determined that ntMSCs were cytoprotective of neonatal rat cardiomyocytes exposed to H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.